Integration challenges impact Stride's Q4 performance

LRN's operating margin will contract by 150-250 basis points in Q4 2024 compared to Q4 2023 specifically attributable to integration costs and operational redundancies

LRN stock price will underperform S&P 500 by 8-15% in the 60 days following Q4 earnings release due to integration-related margin compression concerns

Stride Health (LRN) Q4 2024 revenue will decline by 5-10% year-over-year due to integration disruptions, with recovery beginning in Q1 2025